GMP upgrade to reflect in NHI drug price determination as an incentive.

Published: 2007-06-22 06:59:00

Updated: 2007-06-22 06:59:00

In discussion with the MOHW, the KFDA may implement new incentive plans for the products manufactured at the upgraded GMP (c-GMP) companies to reflect better NHI drug price approval.

The KFDA's incentive plan also included an exemption of regular pharmaceutical supervision against the outstan...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK